Pharmafile Logo

Astellas

Astellas To Present New Data on XOSPATA (gilteritinib) Across the FLT3m+ AML Disease Continuum at ASH 2025 Annual Meeting

Presentations include pooled post-hoc analysis of the Phase 3 ADMIRAL and COMMODORE data on post-transplant gilteritinib resumption in relapsed or refractory FLT3m+ AML Findings from the Phase 3 MORPHO trial in the post-transplant maintenance setting and Phase 1/2 VICEROY trial in newly diagnosed disease highlight how treatment timing, sequencing and combination approaches may influence outcomes. 5...

Astellas and Japanese Foundation for Cancer Research Announce Collaboration to Accelerate Translational and Clinical Oncology Research

Initial collaboration will support projects of mutual interest and help accelerate advancement of Astellas’ early-stage oncology pipeline 2 April 2025 -- Tokyo, Japan -- Astellas Pharma Inc and Japanese Foundation for Cancer Research today announced they have entered into a strategic collaboration to accelerate translational and clinical oncology research. The collaboration leverages Astellas’ unique scientific,...

European Commission Approves Astellas’ PADCEVTM (enfortumab vedotin) in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Urothelial Cancer

First regimen approved in advanced urothelial cancer to demonstrate superiority to platinum-containing chemotherapy, the standard of care for nearly 40 years European Marketing Authorization based on positive overall survival and progression-free survival results from the global Phase 3 EV-302 trial 28 August 2024 -- Tokyo, Japan -- Astellas Pharma Inc today announced that the European...
https://www.astellas.com/en/
2-5-1, Nihonbashi-Honcho, Chuo-Ku, Tokyo 103-8411, Japan

+81-3-3244-3000